Ascentage Pharma Group International (HKSE:06855) EV-to-Revenue : 35.36 (As of Jun. 23, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ascentage Pharma Group International's enterprise value is HK$8,584.6 Mil. Ascentage Pharma Group International's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$242.8 Mil. Therefore, Ascentage Pharma Group International's EV-to-Revenue for today is 35.36.

The historical rank and industry rank for Ascentage Pharma Group International's EV-to-Revenue or its related term are showing as below:

HKSE:06855' s EV-to-Revenue Range Over the Past 10 Years
Min: 21.57 Med: 127.16 Max: 854.37
Current: 35.36

During the past 8 years, the highest EV-to-Revenue of Ascentage Pharma Group International was 854.37. The lowest was 21.57. And the median was 127.16.

HKSE:06855's EV-to-Revenue is ranked worse than
73.89% of 1034 companies
in the Biotechnology industry
Industry Median: 7.69 vs HKSE:06855: 35.36

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-23), Ascentage Pharma Group International's stock price is HK$24.80. Ascentage Pharma Group International's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.87. Therefore, Ascentage Pharma Group International's PS Ratio for today is 28.57.

Ascentage Pharma Group International EV-to-Revenue Historical Data

The historical data trend for Ascentage Pharma Group International's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International EV-to-Revenue Chart

Ascentage Pharma Group International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

334.53

557.16

194.61

30.61

35.95

Ascentage Pharma Group International Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial									194.61	-	30.61	-	35.95

Competitive Comparison of Ascentage Pharma Group International's EV-to-Revenue

For the Biotechnology subindustry, Ascentage Pharma Group International's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascentage Pharma Group International's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's EV-to-Revenue falls into.

Ascentage Pharma Group International EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ascentage Pharma Group International's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	8584.577	/	242.802
	=	35.36

Ascentage Pharma Group International's current Enterprise Value is HK$8,584.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$242.8 Mil.

Ascentage Pharma Group International (HKSE:06855) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ascentage Pharma Group International's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	24.80	/	0.868
	=	28.57

Ascentage Pharma Group International's share price for today is HK$24.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.87.

Ascentage Pharma Group International EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International (HKSE:06855) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ASPHF:USA 36X:Germany

Address

68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000

Website

https://www.ascentagepharma.com

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.

Executives

Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc	2301 Trustee
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Tian Yuan	2201 Interest of corporation controlled by you
Zhao Li	2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo	2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines